Related Experiment Video
Updated: May 11, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
Published on: June 4, 2021
Trials of endovascular therapies or collaterals?
1UCLA Stroke Center, Los Angeles, CA 90095, USA. davidliebeskind@yahoo.com
Abstract:
Several landmark clinical trials of endovascular therapy for acute ischemic stroke have recently jolted the concerted multidisciplinary efforts to develop effective revascularization strategies. Further consideration of these four endovascular stroke trials published in the last year suggests a more fundamental question: are these trials of specific treatments or have the results simply reflected the importance of underlying pathophysiology? Data from IMS III, MR RESCUE, SWIFT and TREVO2 consistently demonstrate the dramatic impact of collateral perfusion in acute ischemic stroke. Such collateral, or parallel, trials of the underlying pathophysiology in stroke reveal that diagnosis or selection of optimal candidates may be paramount to the specific drug or device therapy. Future trials of endovascular therapies may harness the influential role of collaterals as critical selection criteria for intervention, with triage based on imaging rather than time alone. Treating the optimal patient may be more important than chasing an elusive magical therapy.
Insights
Recent endovascular stroke trials highlight the critical role of collateral perfusion. Optimal patient selection based on imaging, rather than time, may be key to successful acute ischemic stroke treatment.
Area of Science:
- Neurology
- Interventional Neurology
- Vascular Neurology
Background:
- Landmark clinical trials in endovascular therapy for acute ischemic stroke have prompted reevaluation of revascularization strategies.
- Recent trials (IMS III, MR RESCUE, SWIFT, TREVO2) suggest underlying pathophysiology, particularly collateral perfusion, significantly impacts outcomes.
Purpose of the Study:
- To investigate whether recent endovascular stroke trial results reflect specific treatment efficacy or the importance of underlying pathophysiology.
- To determine the paramount role of collateral perfusion in acute ischemic stroke outcomes.
Main Methods:
- Analysis of data from four major endovascular stroke trials: IMS III, MR RESCUE, SWIFT, and TREVO2.
- Examination of the impact of collateral perfusion on treatment outcomes in acute ischemic stroke.
Main Results:
- Consistent demonstration of the dramatic impact of collateral perfusion in acute ischemic stroke across all analyzed trials.
- Evidence suggests that patient selection based on underlying pathophysiology (collateral status) is crucial.
Conclusions:
- The effectiveness of endovascular therapy for acute ischemic stroke may be more dependent on patient selection, specifically collateral status, than on the specific device or drug used.
- Future trials should consider collateral status as a critical selection criterion, potentially shifting triage from time-based to imaging-based strategies.
- Focusing on treating the optimal patient, identified through imaging, may be more effective than pursuing a "magical" therapy.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
